Top 114 medical and healthcare startups in London
Nov 26, 2025
|
Like
17
1
Funding: $10M
Emm is developing the first smart menstrual cup with integrated biosensors, which provides data on reproductive and menstrual health. The device functions like a regular menstrual cup, designed to store menstrual blood. The built-in sensor collects data that helps users understand their cycle patterns. Tracking the amount of menstrual fluid you lose each day helps you identify your heaviest days, plan your day and manage your menstrual cycle. Personalized insights can be viewed in the smartphone app. Data collected in the Emm app is encrypted and stored securely with two-factor authentication. Personal identifiers are removed or replaced with codes.
Emm is developing the first smart menstrual cup with integrated biosensors, which provides data on reproductive and menstrual health. The device functions like a regular menstrual cup, designed to store menstrual blood. The built-in sensor collects data that helps users understand their cycle patterns. Tracking the amount of menstrual fluid you lose each day helps you identify your heaviest days, plan your day and manage your menstrual cycle. Personalized insights can be viewed in the smartphone app. Data collected in the Emm app is encrypted and stored securely with two-factor authentication. Personal identifiers are removed or replaced with codes.
2
Funding: $1.1B
Autolus uses advanced CAR-T cell therapy to treat hematological malignancies and solid tumors. While CAR T-cell therapy has revolutionized cancer treatment, it can also cause significant immunotoxicity. Autolus has developed a novel CAR-construct with rapid binding kinetics that is similar to natural T cells and provides improved tolerability in patients with certain types of leukemia. Furthermore, Autolus addresses the issue of immunotoxicity through a personalized dosing approach. The company is also seeking to adopt CAR-T therapy to patients with acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, T-cell lymphoma and solid tumors. It is supporting several ongoing CAR-T clinical trials that are opening up new treatment options and offering new hope for these patients.
Autolus uses advanced CAR-T cell therapy to treat hematological malignancies and solid tumors. While CAR T-cell therapy has revolutionized cancer treatment, it can also cause significant immunotoxicity. Autolus has developed a novel CAR-construct with rapid binding kinetics that is similar to natural T cells and provides improved tolerability in patients with certain types of leukemia. Furthermore, Autolus addresses the issue of immunotoxicity through a personalized dosing approach. The company is also seeking to adopt CAR-T therapy to patients with acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, T-cell lymphoma and solid tumors. It is supporting several ongoing CAR-T clinical trials that are opening up new treatment options and offering new hope for these patients.
3
Funding: $601.7M
Isomorphic Labs provides AI-driven solutions for drug discovery and development.
Isomorphic Labs provides AI-driven solutions for drug discovery and development.
4
Funding: $430M
HOLOGEN AI develops breakthrough technologies that deliver interventional intelligence in healthcare, improving the understanding, design, evaluation, and delivery of treatments.
HOLOGEN AI develops breakthrough technologies that deliver interventional intelligence in healthcare, improving the understanding, design, evaluation, and delivery of treatments.
5
Funding: $322.6M
Medopad connects patients and providers in real time. It also collects data through wearables and lets patients send their data to healthcare professionals. The platform also offers providers and insurers ways to analyze large amounts of data using artificial intelligence and machine learning.
Medopad connects patients and providers in real time. It also collects data through wearables and lets patients send their data to healthcare professionals. The platform also offers providers and insurers ways to analyze large amounts of data using artificial intelligence and machine learning.
6
Funding: $322.6M
Huma offers a health platform used for remote patient monitoring and biological data gathering for preventative healthcare.
Huma offers a health platform used for remote patient monitoring and biological data gathering for preventative healthcare.
7
Funding: $292M
A leading British artificial intelligence company located in the knowledge quarter of London with a focus in health and drug development
A leading British artificial intelligence company located in the knowledge quarter of London with a focus in health and drug development
8
Funding: $290.1M
Beacon Therapeutics is an ophthalmic gene therapy company to treat blinding retinal illnesses and restore and enhance eyesight.
Beacon Therapeutics is an ophthalmic gene therapy company to treat blinding retinal illnesses and restore and enhance eyesight.
9
Funding: $275.8M
Flo Health is a developer of Flo, the fastest growing AI-driven women’s health product that encompasses solutions for girls and women at every stage of their life (start of menstruation, cycle tracking, preparation for conception, pregnancy, early motherhood, menopause).
Flo Health is a developer of Flo, the fastest growing AI-driven women’s health product that encompasses solutions for girls and women at every stage of their life (start of menstruation, cycle tracking, preparation for conception, pregnancy, early motherhood, menopause).
11
Funding: $213M
Achilles Tx's mission is to develop next-generation, patient-specific therapies that harness the immune system to destroy cancer cells
Achilles Tx's mission is to develop next-generation, patient-specific therapies that harness the immune system to destroy cancer cells
12
Funding: $206.6M
YuLife is a provider of life insurance and policies providing income in the event of critical illness.
YuLife is a provider of life insurance and policies providing income in the event of critical illness.
13
Funding: $205.5M
Pulmocide is focused on the development of inhaled medicines for the treatment of viral and fungal infections of the respiratory tract.
Pulmocide is focused on the development of inhaled medicines for the treatment of viral and fungal infections of the respiratory tract.
15
Funding: $188M
Pheon Therapeutics is developing a portfolio of next-generation ADCs with the potential to treat difficult-to-treat solid tumors. Recognizing that there is no one-size-fits-all solution in ADC development, Pheon takes an adaptive approach to ADC development. Using monoclonal antibodies (mAbs) against both novel and clinically proven ADC targets and equipping them with either proprietary platform active substances with a novel mechanism of action or pre-existing linker combinations, Pheon precisely ensures the balance of safety and efficacy for each target. Pheon has assembled a world-class leadership team with two decades of ADC experience. The company is currently conducting Phase I clinical trials of its lead asset, which has demonstrated robust preclinical data, including in vivo efficacy, NHP safety and extensive expression profiling in tumors and healthy tissue.
Pheon Therapeutics is developing a portfolio of next-generation ADCs with the potential to treat difficult-to-treat solid tumors. Recognizing that there is no one-size-fits-all solution in ADC development, Pheon takes an adaptive approach to ADC development. Using monoclonal antibodies (mAbs) against both novel and clinically proven ADC targets and equipping them with either proprietary platform active substances with a novel mechanism of action or pre-existing linker combinations, Pheon precisely ensures the balance of safety and efficacy for each target. Pheon has assembled a world-class leadership team with two decades of ADC experience. The company is currently conducting Phase I clinical trials of its lead asset, which has demonstrated robust preclinical data, including in vivo efficacy, NHP safety and extensive expression profiling in tumors and healthy tissue.
16
Funding: $162.7M
CHARM Therapeutics uses deep learning on 3D molecular configurations to develop molecule therapeutics to target pathogenic proteins.
CHARM Therapeutics uses deep learning on 3D molecular configurations to develop molecule therapeutics to target pathogenic proteins.
17
Funding: £125M
Purespring Therapeutics is an AAV gene therapy company focused on the kidney globally.
Purespring Therapeutics is an AAV gene therapy company focused on the kidney globally.
19
Funding: $130.7M
Numan is a startup which aims to tackle your tackle problem erectile dysfunction.
Numan is a startup which aims to tackle your tackle problem erectile dysfunction.
20
Funding: $118M
Proximie is a secure software solution that expands virtual surgical collaboration enabling surgeons to share expertise through AR.
Proximie is a secure software solution that expands virtual surgical collaboration enabling surgeons to share expertise through AR.
